Navigation Links
Lupus Treatment May Soon Take Leap Forward
Date:12/25/2010

By Dennis Thompson
HealthDay Reporter

FRIDAY, Dec. 24 (HealthDay News) -- For years now, doctors have made slow, incremental progress in the treatment of lupus, a chronic autoimmune condition that can wrack the body and seriously affect a person's health.

But researchers now are preparing for a potential major leap forward.

A new medication that could be an effective new treatment for the disease was endorsed in mid-November by an advisory panel of the U.S. Food and Drug Administration and recommended for approval. Though the FDA is not bound by its advisory committees' recommendations, it usually follows them.

"There is real optimism there may be a drug approved for the treatment of lupus for the first time in 54 years," said Dr. Mary Anne Dooley, an associate professor at the University of North Carolina Kidney Center.

Lupus primarily affects women. Nine out of 10 people who have lupus are women. It also appears to be more common among black, Hispanic, Asian and Native American women than white women.

The disease causes the immune system to begin harming the organs and the systems of the body. "Your immune system becomes hyperactive, and, instead of defending you from infection, it attacks parts of your body," Dooley said.

According to Dooley and the U.S. National Institutes of Health, the most common symptoms of lupus include:

  • A "butterfly" rash across the nose and cheeks.
  • Skin rashes elsewhere.
  • Skin photosensitivity.
  • Joint pains and stiffness.
  • Muscle aches and pain.
  • Hair loss.
  • Fatigue.
  • Fever not linked to any other illness.
  • Anemia.
  • Difficulty concentrating or remembering.

"Lupus primarily attacks the skin and the joints, but any organ can be affected," said Dr. Cynthia Aranow, an associate investigator with the Feinstein Institute for Medical Research at the North Shore-Long Island Jewish Health System in New York.

When the organs are affected, people with lupus can suffer serious health effects. They face an increased risk for kidney damage and other long-term health problems, and "women with lupus are 50 times more likely to develop heart disease than women without lupus," Dooley said.

Researchers have not yet figured out what prompts lupus. Studies suggest that genetics probably play a large role, but there also seems to be another factor that triggers the disease, Aranow said.

"We know it's more than the genes," she said. "If one twin has lupus, the risk of the other twin developing lupus is only 25 to 50 percent."

Improvements in lupus treatment have helped people live longer and healthier lives. In 1950, a person diagnosed with lupus had a 50 percent chance of surviving two years, Aranow said. Today, the 10-year survival rate for someone with lupus very nearly mirrors that of the overall population.

However, the improvements have not come from research specifically targeted to lupus. The last lupus drug to receive approval, Plaquenil, was approved in the 1950s, Dooley said.

Instead, doctors have improved lupus treatment through the use of medications created for other diseases. "Rheumatologists beg, borrow and steal medications from other specialties," Aranow said. These include immunosuppressive drugs and newer anti-malarials, anti-inflammatories and corticosteroids.

But that could change soon with Benlysta (belimumab), which has shown promise as a lupus treatment.

Benlysta works by downregulating the communication between the immune system's T and B cells, Dooley said. The T cells govern the immune response and tell B cells what sort of antibodies to produce.

"It doesn't completely prevent communication, but it reduces the hyperactivity," Dooley said. "You're still able to fight off infection and have your immune system be effective this way, but you wouldn't have all these markers of immune hyperactivity."

Benlysta has been boosted by two major studies that have come out in the past year showing its effectiveness. And, although the FDA had expressed concerns about safety, questioning whether its use might be linked to depression and suicide, the advisory panel examined safety data and decided otherwise.

At the same time, lupus researchers continue to pinch medications and treatments from other specialties. Research is underway to see whether an immunosuppressive drug created to maintain kidney transplants, mycophenolate mofetil (MMF), could be an effective lupus drug. It has become generic and, therefore, less expensive, and it may have fewer side effects than other lupus medications, Dooley said.

"It's important for people [with lupus] to realize that they're not alone, that the outlook is much better and there are all sorts of resources available," Aranow said.

More information

The Lupus Foundation of America has more about lupus.

For more on lupus, read about one woman's story.

SOURCES: Mary Anne Dooley, M.D., M.P.H., associate professor, medicine, University of North Carolina, Chapel Hill, N.C.; Cynthia Aranow, M.D., associate investigator, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, Manhasset, N.Y.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
2. Antibodies linked to cardiovascular disease increase in patients with active lupus
3. New Clues to Lupus Link With Heart Disease
4. Psychotherapy Can Help People With Lupus Cope
5. Sisters Helping Sisters: A New Lupus Research Study to Follow Sisters of Lupus Patients
6. Lupus Awareness Month Kicks Off at Rockefeller Center: EHE International Donates Display Window to S.L.E. Lupus Foundation for May
7. Genealogy may affect clinical differences in systemic lupus erythmatosus patients
8. Chinese systemic lupus erythematosus data reveal differences in epidemiology across continents
9. Researchers uncover biological rationale for why intensive lupus treatment works
10. Overactive Blood Platelets May Play Role in Lupus
11. Correction: Abatacept found ineffective in treatment of non-life threatening lupus
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lupus Treatment May Soon Take Leap Forward
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: